聚焦
2017年5月16日至18日，藥石科技PharmaBlock美國商務(wù)拓展團(tuán)隊(duì)參加了在費(fèi)城舉辦的，世界制藥原料北美展暨美國國際精細(xì)化工展覽會(CPhI North America & InformEx)。今年是CPhI在美國的首秀，主辦地費(fèi)城是全球醫(yī)藥行業(yè)最發(fā)達(dá)的城市之一，周邊匯聚了超過3000家世界領(lǐng)先的制藥公司、生物技術(shù)企業(yè)和研發(fā)機(jī)構(gòu)，為這次展會帶來了更多新的機(jī)遇。
在CPhI NA舉辦期間，由C&EN (美國化學(xué)會旗下《化學(xué)與工程新聞》雜質(zhì)) 出版的會刊Show Daily專門對藥石科技進(jìn)行了報道，刊登了有關(guān)藥石科技與全球頂尖研發(fā)型制藥企業(yè)Agios Pharmaceutical Inc. 簽訂商業(yè)化供應(yīng)合作協(xié)議的消息。
藥石科技憑借在合成化學(xué)、工藝開發(fā)和生產(chǎn)方面的卓越能力，正在為越來越多的客戶在新藥研究、開發(fā)和商業(yè)化的過程中提供更全面的產(chǎn)品和服務(wù)，建立長期穩(wěn)定的合作關(guān)系。
（打開Show Daily閱讀全文）
圖：Show Daily藥石科技報道
圖：藥石科技美國商務(wù)拓展團(tuán)隊(duì)參展
READ THE NEWS
報道全文
PharmaBlock Inks New Commercial Supply Agreement with Agios
PharmaBlock Sciences (Nanjing), Inc., a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process, has entered a new Commercial Supply Agreement for Drug Substance Starting Materials with Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, as part of the commercial launch readiness.
Under this agreement, PharmaBlock will continuously provide Agios with drug substance starting materials and intermediates for commercial production.
PharmaBlock and Agios have been involved in a long-term collaboration, from synthesis of lab-scale building blocks to bulk manufacturing of RSMs, as Agios’ drug R&D project moves on to later development stages. “We are pleased to have PharmaBlock as our strategic partner. With their capabilities in medicinal synthesis, process R&D, and manufacturing, we have collaborated from research to development to commercial.” said Ms. Wendy Xia, Director of Commercial Supplies at Agios, “It is an exciting story that we both experience the ‘scale-up’ together, and enter this commercial partnership eventually.”
"The Commercial Supply Agreement further strengthens our already productive relationship with Agios, one of our most valued customers for many years. It is our honor to be a part of Agios’ life-saving drug R&D projects and witness every milestone they have achieved along the way. We will continue to deliver our firm commitment to quality and custom satisfaction.” said Dr. Haijun Dong, Chief Executive Officer of PharmaBlock.